Health-tech startup Biopeak has raised $2.7 million in a follow-on funding round led by NKSquared, the investment arm of Zerodha cofounder Nikhil Kamath. The round marks Kamath’s second investment in the company, following his $1.43 million infusion into the health optimisation startup in August 2024.
According to the company, the newly raised capital will be used to scale its operations, including the launch of a new clinic, and to strengthen its diagnostics capabilities, proprietary artificial intelligence tools, research initiatives, and clinical programmes.
Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak operates at the intersection of AI, diagnostics, and preventive healthcare, with a focus on improving healthspan and longevity. The startup follows a “family health office” model, offering personalised, long-term health plans designed to optimise performance and resilience.
Biopeak’s platform integrates a range of advanced diagnostic methods, including organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythm analysis, and imaging such as MRI, CT, DXA, and ECHO. Its in-house clinics deliver specialised care using data-driven insights across areas like nutrition, sleep, and stress management.
Based in Bengaluru, the startup caters primarily to high achievers, executives, and women, combining specialist-led programmes, wearable data, and AI-generated insights tailored to Indian biology and disease patterns. Its approach emphasises early risk identification, longitudinal health tracking, and targeted interventions.
Over the past year, Biopeak said it has expanded both its client base and clinical services amid growing interest in structured longevity solutions. The company opened its first clinic in Bengaluru last year and plans to launch a second facility in the coming month.
